Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23356599 | 0.81 | ACP3 (0.34) | KMT2AMEN1MAPT | |
| SCHEMBL29657202 | 0.75 | BRD4 (0.44) | KMT2AMEN1MAPTALDH1A1HPGD | |
| SCHEMBL28162214 | 0.72 | BRD4 (0.32) | MAPT | |
| SCHEMBL29657183 | 0.72 | HDAC4 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL29657126 | 0.70 | DRD2 (0.32) | — | |
| SCHEMBL28162681 | 0.70 | MAPT (0.33) | KMT2AMEN1MAPT | |
| SCHEMBL28182028 | 0.68 | MAPT (0.33) | KMT2AMEN1MAPTALDH1A1HPGD | |
| SCHEMBL29657243 | 0.65 | ALDH1A1 (0.43) | KMT2AMEN1MAPTALDH1A1HPGD | |
| SCHEMBL29657203 | 0.65 | GPR3 (0.51) | KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL29657159 | 0.64 | BRD4 (0.34) | KMT2AMEN1MAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | claimed |
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286240-B2 | Catalyst bound alpha radical and synthesis of OXO compounds using the same | CBR1, POR, CAT | KMT2A 2616/4885MEN1 1234/4885MAPT 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.